Strategic partnerships Ravgen collaborates with TestSource Lab to offer non-invasive prenatal DNA paternity testing, indicating a channel could be expanded with additional lab partnerships and white-label arrangements to scale testing volume.

IP and innovation Ravgen has a history of patent-related litigation around fetal cell-free DNA methods, suggesting a focus on protecting and monetizing unique non-invasive prenatal testing technologies; potential sales angles include licensing, collaborations, or co-development opportunities with diagnostic manufacturers.

Clinical expansion The company targets a broad set of single-gene disorder diagnostics and paternity testing early in pregnancy, presenting opportunities to upsell to obstetrics clinics, maternal-fetal medicine specialists, and fertility centers seeking earlier and broader genetic screening capabilities.

Funding and scale With reported revenue in the low tens of millions and modest external funding, Ravgen may prioritize revenue-generating partnerships and contract work with larger labs or healthcare providers to accelerate growth and justify further investment.

Market positioning Operating in a competitive landscape with large players, Ravgen can leverage its niche in non-invasive prenatal diagnostics to pursue specialty lab networks, targeted payer conversations, and co-branding opportunities with established diagnostic brands to broaden market reach.